12th Congress of the European Hematology ... - Haematologica

More documents

Recommendations

Info

12 th Congress of the European Hematology Association Therapy of non-Hodgkin's lymphoma 0297 QUALITY OF LIFE IN PATIENTS WITH NON-HODGKINS-LYMPHOMA DURING MAINTENANCE THERAPY WITH THE ANTI-CD20 ANTIBODY RITUXIMAB M. Witzens-Harig, 1 M. Reiz,1 C. Heiss, 2 A. Benner, 2 M. Hensel, 1 K. Neben, 1 P. Dreger, 1 A. Krämer, 1 A.D. Ho 1 1 University of Heidelberg Hospital, HEIDELBERG; 2 German Cancer Research Center, HEIDELBERG, Germany The introduction of rituximab into the treatment of malignant lymphomas of the B-cell lineage has had a major impact on the management of these diseases. In diffuse large B-cell lymphomas (DLBCLs) and follicular lymphomas (FLs) several multicenter prospective randomized trials consistently demonstrated an improved outcome when rituximab was added to chemotherapy. In addition, prolonged exposure to rituximab as maintenance therapy has been benefical in patients with FL and mantle cell lymphoma (MCL). For patients, the effect of any prolonged antitumor therapy on the quality of life (QoL) is a very important question. However, so far the question whether rituximab maintenance therapy may impair QoL in patients with Non-Hodgkins-lymphoma remains unanswered. To investigate this subject , we have performed a prospective randomized trial of rituximab maintenance therapy (8 cycles rituximab 375 mg/m 2 every 3 months) versus observation in patients with CD20 + B-cell Non-Hodgkins-Lymphoma in our institution. Between July 2002 and December 2005, 106 patients (pts) were included into the trial. QoL was assessed with the standardized questionnaires EORTC-QLQ-C30 and EuroQol-5D. After statistical analysis with the Wilcoxon signed-rank test, we found no significant differences of the QoL between the rituximab treatment group and the observation group. We conclude that rituximab maintenance therapy is safe and does not impair quality of life in this patient population. 0298 RITUXIMAB MAINTENENANCE THERAPY IN CD20+ B-CELL NON-HODGKIN-LYMPHOMA FIRST RESULTS OF A MULTICENTER PROSPECTIVE RANDOMISED PHASE II STUDY M. Witzens-Harig, 1 M. Hensel, 1 J. Schmier, 1 K. Neben, 1 A. Benner, 2 P. Dreger, 1 C. Kuhn, 3 I. Schmidt-Wolf, 4 A. Krämer, 1 A.D. Ho1 1 University of Heidelberg Hospital, HEIDELBERG; 2 German Cancer Research Center, HEIDELBERG; 3 University of Heidelberg, Mannheim, MANNHEIM; 4 University of Bonn, BONN, Germany Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy in patients with CD20 + B-cell Non-Hodgkins-Lymphoma. After completion of standard treatment patients were randomized to either observation or maintenance therapy with rituximab (375 mg/m 2 ) every 3 months for 2 years. Patients after first line therapy as well as relapse patients were included in the study. Patients with aggressive lymphoma were enrolled if they had achieved a complete response (CR) after initial treatment. Patients with aggressive lymphoma with residual tumor mass were examined with positrone emission tomography (PET) and qualified for randomization if PET showed no signs of tumor activity. Patients with indolent lymphoma qualified for the study if at least a partial response (PR) was achieved. After recruitment of 172 patients a planed interim analysis was performed. Complete data sets of 162 patients (pts) with CD20 + B-cell Non-Hodgkins-Lymphoma were evaluable for analysis. Histological subtypes included diffuse large cell lymphoma (69 pts), follicular lymphoma (41 pts), mantle cell lymphoma (18 pts), primary mediastinal lymphoma (15 pts), marginal zone lymphoma (9 pts), Burkitt’s lymphoma (3 pts), immunocytoma (2 pts), primary intestinal lymphoma (1 pt), hairy cell leukemia (1 pt), chronic lymphocytic leukemia (1 pt) and unclassified B-cell lymphoma (2 pts). The interim analysis showed that event free survival was significantly prolonged in the rituximab maintenance group compared to the observation group (p
(range, 1-6) and 11 treatment cycles (range, 6-22). All patients were evaluated for response and toxicities. The total objective response rate was 35.0% (1 CR, 6 PRs), and 55.6% in low-grade lymphoma, 18.2% in DLB- CL. There was a trend of higher response in low-grade lymphoma than DLBCL, but this difference was statistically insignificant (two sided Fisher’s exact test, p=0.16). Adverse events were primarily hematologic toxicities; the incidence of grade 4 neutropenia and thrombocytopenia was each 25.0%. The treatment-related mortality was observed in one patient, who had been previously treated with high-dose chemotherapy plus TBI with autologous stem cell transplantation. Summary and conclusions. RIT with I-131 rituximab seems to be effective and tolerable in refractory low-grade B-cell NHL, although modest activity in refractory DLBCL. Further studies to define the efficacy of I-131 rituximab in DLB- CL are warranted, such as consolidation RIT followed by standard chemotherapy or high-dose RIT with autologous stem cell transplantation. 0301 RITUXIMAB AND CHLORAMBUCIL AS FIRST LINE TREATMENT OF LOW-GRADE OCULAR ADNEXAL LYMPHOMAS L. Nassi, 1 L. Rigacci, 1 M. Puccioni, 1 E. Polito, 2 S. Mappa, 1 S. Dal Pozzo, 1 R. Alterini, 1 V. Carrai, 1 B. Puccini, 1 A. Bosi1 1 Careggi Hospital, FL; 2 Policlinico Le Scotte, SIENA, Italy Background. Ocular adnexal lymphomas (OALs) represents 5-15% of primary extranodal lymphomas, and are constituted largely by extranodal marginal zone lymphomas (EMZL). Radiotherapy is associated to high rates of local disease control, but also to the risk of relapse and immediate and delayed complications, such as xerophtalmy, corneal ulcerations, cataract and retinal damage. Surgery is a feasible option, but not always satisfactory in terms of disease control. Single-agent chemotherapy with alkylating agents is used for the treatment of lowgrade lymphomas, including OALs. Rituximab, a chimeric anti-CD20 monoclonal antibody, is effective in EMZL and in OALs. Aims. We investigated the efficacy and the safety of a combination of chlorambucil and rituximab as first line treatment in patients with OALs. Methods. Patients with histologically proven low-grade OALs were enrolled in this study. Staging included CT-scan of the orbit, neck, chest and abdomen, MR of the orbit, and bone marrow biopsy, and was done according to Ann Arbor classification. Treatment consisted of chlorambucil (0,1 mg/Kg/die for 45 days, then on days 1 to 15 monthly for 4 months) and rituximab (375 mg/sqm weekly for 4 doses, then monthly for 4 infusions). Toxicities were reported according to WHO criteria. At the end of treatment patients were restaged clinically and with a MR of the orbit. Results. Since November 2003 to December 2005 nine consecutive histologically proven low-grade OALs (eight EMZL, a grade I follicular lymphoma) have been treated according to this protocol. The median interval between onset of the first symptoms and diagnosis was 13 months (range, 4 months - 3 years). Six patients were female (66%). Median age at diagnosis was 78 years (range, 56-86 years). Disease was localized in the conjunctiva in four patients, in the lacrimal glands in 3 patients and in other orbital sites in the last two patients. Eight patients had a stage I disease, one stage IV, and no patient presented B-symptoms. LDH was within normal range in all patients, ECOG-PS was 0 in all patients. All patients completed the treatment without delay; there was no grade III- IV toxicities nor hospitalizations. Five patients had grade 1-2 rituximab infusion-related reactions usually during the first infusion. We did not observe infectious complications. Haematological toxicity was mild. At the end of treatment local symptoms were not present: eight patients (89%) were in CR, and the remaining patient (11%) obtained a PR. After a median follow-up of 22 months (range, 10-38 months) all patients are alive and we did not observe disease progressions; the median EFS was 19 months (range, 8-36 months). All patients underwent periodic ophthalmologic follow-up visits: we did not report ocular toxicities, and all patients conserved a normal visual function, including acuity. Conclusions. The combination of rituximab and chlorambucil proved to be a safe, feasible and effective therapy for primary OALs. However, a longer follow-up would be necessary to determine the long-term efficacy of this treatment. 12 th Congress of the European Hematology Association 0302 PHASE I STUDY OF SMILE CHEMOTHERAPY FOR ADVANCED-STAGE OR RELAPSED/REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA/LEUKEMIA Y.L. Kwong, 1 M. Yamaguchi, 2 R. Suzuki, 3 W.S. Kim, 4 Y. Hasegawa, 5 K. Izutsu, 6 J. Suzumiya, 7 T. Okamura, 8 S. Nakamura, 3 K. Kawa, 9 K. Oshimi10 1 University of Hong Kong, HONG KONG, China; 2 Mie University, TSU, Japan; 3 Nagoya University, NAGOYA, Japan; 4 Samsung Medical Center, SEOUL, South-Korea; 5 Tsukuba University Hospital, TSUKUBA, Japan; 6 University of Tokyo, TOKYO, Japan; 7 Fukuoka University, FUKUOKA, Japan; 8 University of the Ryukyus, NISHIHARA, Japan; 9 Osaka Medical Center, OSAKA, Japan; 10 Juntendo University, TOKYO, Japan; Background. Extranodal NK/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are rare, and their standard therapy has not been established. They are Epstein-Barr virus (EBV)-associated lymphoid malignancies, and lymphoma/leukemia cells express P-glycoprotein leading to multi-drug resistance (MDR) of the disease. Almost all patients with stage IV, relapsed, and refractory diseases die within 1 year. Aims. To establish a more effective induction therapy for these neoplasms with untreated stage IV or relapsed/refractory state, we conducted a dose escalating feasibility study of a newly designed chemotherapeutic regimen, SMILE [Steroid=dexamethasone (DMS) 40 mg/body d2-4 IV, Methotrexate (MTX) 2 g/m 2 d1 6hr IV, Ifosfamide (IFM) 1.5 g/m 2 d2-4 IV, L-asparaginase (L-asp) 6000U/m 2 d8,10,12,14,16,18,20 IV, and Etoposide (ETP) 100 mg/m 2 d2-4 IV; every 28 days]. SMILE comprised MDR-unrelated agents and ETP that shows both in vitro and in vivo efficacy for EBV-associated lymphoproliferative disorders. Methods. Primary endpoint is MTD (maximum tolerated dose), and secondary endpoints are the overall response rate (ORR) and the complete response (CR) rate. Pts with newly diagnosed stage IV diseases (including aggressive NK-cell leukemia), first relapsed/ recurrent diseases after CR/PR, refractory (either NC or PD) diseases with first-line chemotherapy, 15-69 years of age, and PS 0-2 were eligible. A standard 3+3 design was used to evaluate dose-limiting toxicities (DLTs). The doses of DMS, IFM, and L-asp were fixed. Four dose levels of MTX/ETP were planned to be evaluated. Results. At Level 1, 6 pts with extranodal NK/T-cell lymphoma, nasal type were enrolled, and showed the following features; age 28-69 yrs (median 48), M:F=5:1, newly-diagnosed stage IV: 3, 1st relapse: 2, primary refractory: 1, BM involvement: 2, elevated serum LDH: 4, and PS0: 2 , PS1: 3, PS2: 1. Among the first 3 pts, 1 pt died from sepsis with grade 4 neutropenia due to disease and delayed initiation of G-CSF administration. 1 pt developed grade 3 infection and hypofibrinogenemia. The remaining 1 pt did not develop DLT other than transient grade 3 hyponatremia, and obtained a CR. We made a protocol amendment to initiate G-CSF administration from day 6, and proposed to register additional 3 pts in Level 1. It was approved by the Data and Safety Monitoring Committee. Additional 3 pts developed DLTs (grade 3 APTT 1, grade 3 gamma-GTP 1, grade 3 hyponatremia 2, and grade 3 hyperglycemia 1) that were all manageable, and pts recovered from the toxicities rapidly. The incidence of grade 4 neutropenia was comparable, but grade 3/4 leukopenia/ anemia/ thrombocytopenia were less frequent than the first 3 pts. Of all 6 enrolled pts, 3 achieved CR, 1 PR, 1 NR, and 1 NE.%ORR was 67%, and%CR was 50%. Summary and Conclusions. Our results suggest that dose level 1 of SMILE is feasible and promising for advanced, refractory or relapsed NK/T-cell lymphoma. To determine the efficacy and feasibility of SMILE in a large number of cases, we will start the subsequent phase II study of SMILE in spring 2007. 0303 RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH FOLLICULAR LYMPHOMA. A COST-EFFECTIVE STRATEGY? C. Francisco J., 1 E. Conde, 2 P. Giraldo, 3 J. Gomez Codina, 4 M. Provencio, 5 E. Rios, 6 A. Rueda, 7 C. Rubio-Terres, 8 C. Varela9 1 Hospital Universitario Puerta del Mar, CADIZ; 2 Hospital U. Marqués de Valdecilla, SANTANDER; 3 Hospital Universitario Miguel Servet, ZARAGOZA; 4 Hospital Universitario La Fe, VALENCIA; 5 Hospital Universitario Puerta de Hierro, MADRID; 6 Hospital Virgen del Rocío, SEVILLA; 7 Hospital Virgen de la Victoria, MALAGA; 8 HEALTH VALUE, MADRID; 9 Roche Farma, MADRID, Spain; Background. Rituximab, a chimeric anti-CD20 monoclonal antibody, has shown to significantly improve overall survival (OS) (p=0.011) and progression free survival (PFS) (p
Page 1 and 2:
haematologica the hematology journa
Page 3 and 4:
Information for readers, authors an
Page 5 and 6:
EHA Executive Board E. Hellström-L
Page 7 and 8:
Poster session I POSTER SESSION POS
Page 9 and 10:
12 th Congress of the European Hema
Page 11 and 12:
dasatinib. Methods. We studied Ikar
Page 13 and 14:
Expression of the oncogene H-Ras an
Page 15 and 16:
is the gene for the erythropoietin
Page 17 and 18:
safety of a slow-release liposomal
Page 19 and 20:
0029 OUTCOME OF THE TREATMENT OF AD
Page 21 and 22:
drug-induced apoptotic response of
Page 23 and 24:
41% in the PI3K- group (p=0.001). I
Page 25 and 26:
Acute myeloid leukemia - Clinical I
Page 27 and 28:
to 60 years (n=116, or 72%) receive
Page 29 and 30:
0056 PROGNOSTIC SIGNIFICANCE OF FLT
Page 31 and 32:
Anemia and Bone marrow failure 0061
Page 33 and 34:
tified with the current protocol. S
Page 35 and 36:
new cases of lead poisoning due to
Page 37 and 38:
icance, from baseline to week 6 (p
Page 39 and 40:
0086 THROMBELASTOGRAPHIC CHART RELI
Page 41 and 42:
trials. The aim of this retrospecti
Page 43 and 44:
tant function in this disease, nega
Page 45 and 46:
ed to a favorable outcome. Bialleli
Page 47 and 48:
stronger levels of p21 in the cell
Page 49 and 50:
hematological centers in one countr
Page 51 and 52:
ure 1). Conclusions. Results for re
Page 53 and 54:
patients. After a median follow-up
Page 55 and 56:
Cytogenetics and Molecular diagnost
Page 57 and 58:
0135 ROUTINE DETECTION OF CYTOGENET
Page 59 and 60:
(MMolR, defined as a BCR-ABL x 100
Page 61 and 62:
0146 ARSENIC TRIOXIDE INDUCES ACCUM
Page 63 and 64:
tinguish between genotypic B-cell l
Page 65 and 66: Genomics and proteomics 0158 PLASMA
Page 67 and 68: 0164 EVALUATION OF MULTIPLEX LIGATI
Page 69 and 70: each patient’s replicate conditio
Page 71 and 72: 0174 RELATION BETWEEN LOW PML-RARα
Page 73 and 74: 0179 ESHAP VS GIN AS SALVAGE AND MO
Page 75 and 76: Immunology and gene therapy 0184 EA
Page 77 and 78: Cell viability was not affected by
Page 79 and 80: month is not relevant to chronic Gv
Page 81 and 82: Infection and supportive care I 020
Page 83 and 84: 0206 POTENTIAL ROLE OF CMV IN THE O
Page 85 and 86: 3H-thymidine uptake in cell culture
Page 87 and 88: 0217 TUBERCULOSIS AMONG A COHORT OF
Page 89 and 90: 0222 COMPARISON OF IWG 2006 AND IWG
Page 91 and 92: tem (IPSS) to h-MDS was also invest
Page 93 and 94: PCH97-19) were studied. Conventiona
Page 95 and 96: of erythroid colonies was reduced i
Page 97 and 98: 0245 POTENT AND SELECTIVE INHIBITIO
Page 99 and 100: 0250 INACTIVATION OF SUPPRESSOR OF
Page 101 and 102: Bortezomib 1.3 mg/m 2 days 1,4,8,11
Page 103 and 104: Response was defined according to E
Page 105 and 106: G-CSF can be used in neutropenic pa
Page 107 and 108: ence and functional activity of CD8
Page 109 and 110: itating tumor development, or engag
Page 111 and 112: phoma and SNT-13, -15 were establis
Page 113 and 114: usage (2/20 ie 10%) were observed.
Page 115: 0294 MYCOSIS FUNGOIDES. IMMUNOHYSTO
Page 119 and 120: 0306 RISK-ADAPTED IMMUNOCHEMOTHERAP
Page 121 and 122: functional activity was confirmed b
Page 123 and 124: No major toxicity, neither hematolo
Page 125 and 126: enewal potential of X-RAR-positive
Page 127 and 128: (50-99) respectively. Serial analys
Page 129 and 130: cell-interaction, adhesion and acti
Page 131 and 132: 0340 ALTERED FIBRIN CLOT STRUCTURE
Page 133 and 134: Conclusions. This study demonstrate
Page 135 and 136: 0354 FACTOR V LEIDEN HOMOZYGOUS GEN
Page 137 and 138: Results. From July 2005 through Mar
Page 139 and 140: 0364 CLINICAL EFFICACY OF OXALIPLAT
Page 141 and 142: one marrow and peripheral blood ste
Page 143 and 144: ecently suggested (Boissel et al.,
Page 145 and 146: 0378 SAFETY AND EFFICACY OF THE TER
Page 147 and 148: Cytogenetics and molecular diagnost
Page 149 and 150: 0385 CYTOPLASMIC MUTATED NUCLEOPHOS
Page 151 and 152: 0390 ELTROMBOPAG RAISES PLATELET CO
Page 153 and 154: factor for the achievement of CR wa
Page 155 and 156: The cases of RAS showed two peaks o
Page 157 and 158: is 85%. Seven out of the 25 relapse
Page 159 and 160: 0409 FRACTIONATED RADIOIMMUNOTHERAP
Page 161 and 162: 0414 COMPARATIVE ANALYSIS OF THE CO
Page 163 and 164: successfully managed with GM-CSF di
Page 165 and 166: 49% for PCR positive patients (95%
Page 167 and 168:
+8 (1 PR+1 HI) and 14/24 pts with c
Page 169 and 170:
(e.g. bcr-abl leading to CML). CSC
Page 171 and 172:
0438 TERC MUTATIONS ANALYSIS IN PAT
Page 173 and 174:
observed in all mice. Analysis of l
Page 175 and 176:
ex-vivo expansion of HUCB-derived H
Page 177 and 178:
ic kidney disease in univariate or
Page 179 and 180:
One hundred eleven CN AML patients,
Page 181 and 182:
to asses intestinal epithelial dama
Page 183 and 184:
genesis of acute myeloid leukaemia
Page 185 and 186:
polymorphism at nucleotide 4889 of
Page 187 and 188:
expression along with a decreased C
Page 189 and 190:
0487 MUTATIONAL STATUS OF NUCLEOPHO
Page 191 and 192:
previously reported, a single cours
Page 193 and 194:
0497 SINGLE AGENT CLORETAZINE (VNP4
Page 195 and 196:
ly received melphalan-based chemoth
Page 197 and 198:
were similar among the 3 groups. Ho
Page 199 and 200:
Methods. Several read-out systems w
Page 201 and 202:
0518 SERUM AND CELLULAR EXPRESSION
Page 203 and 204:
0523 DNA REPAIR INHIBITION IN RESTO
Page 205 and 206:
held true when BMI-1 expression was
Page 207 and 208:
Ph + cells in the bone marrow). We
Page 209 and 210:
derivative chromosome (4p16, 7p14,
Page 211 and 212:
0545 STABILIZED BONE MARROW IS NOT
Page 213 and 214:
obtained in low (Sokal) risk patien
Page 215 and 216:
median dose intensity being 800 (21
Page 217 and 218:
from pivotal clinical trials. Metho
Page 219 and 220:
Cytogenetics and Molecular diagnost
Page 221 and 222:
to set up and optimize a D-HPLC-bas
Page 223 and 224:
0576 WESTERN BLOT IDENTIFICATION OF
Page 225 and 226:
Basic disease was AML (n=5), ALL (n
Page 227 and 228:
0588 EXTRACORPOREAL PHOTOPHORESIS F
Page 229 and 230:
acquire a cytolytic capacity agains
Page 231 and 232:
informed vignettes describing healt
Page 233 and 234:
using CHOP-21 in the UK, pegfilgras
Page 235 and 236:
0609 SOFT TISSUE COMPLICATIONS IN P
Page 237 and 238:
inding lectin (MBL) gene by polymer
Page 239 and 240:
all infection rate (p=0.12) as well
Page 241 and 242:
Myelodysplastic syndromes II 0623 M
Page 243 and 244:
formation (in total 28 samples). Ti
Page 245 and 246:
sion. In addition, confocal analysi
Page 247 and 248:
Myeloproliferative disorders - Clin
Page 249 and 250:
open-label, multi-centre study enro
Page 251 and 252:
iopsies after 6 and 12 months treat
Page 253 and 254:
Myeloproliferative disorders Chroni
Page 255 and 256:
ash, muscolar cramps, diarrhoea, he
Page 257 and 258:
induced significant apoptosis (mean
Page 259 and 260:
Myeloma and other monoclonal gammop
Page 261 and 262:
the therapy of choice for POEMS is
Page 263 and 264:
er patient does not indicate such t
Page 265 and 266:
Myeloma and other monoclonal gammop
Page 267 and 268:
secutive patients with MM, referred
Page 269 and 270:
whether gene expression values may
Page 271 and 272:
0705 THE SHIFT OF TREATMENT FOR NAS
Page 273 and 274:
0710 CLINICO-PATHOLOGICAL FEATURES,
Page 275 and 276:
patients presented a stage IV disea
Page 277 and 278:
plete remission or recurrent diseas
Page 279 and 280:
known at NHL diagnosis, were includ
Page 281 and 282:
0731 THE IMPACT OF HIV ON NON-HODGK
Page 283 and 284:
patients had died of their underlyi
Page 285 and 286:
scripts and proteins most affected
Page 287 and 288:
modulated after 24 h (37 up- and 59
Page 289 and 290:
0753 A SUSTAINED REMISSION OF IDIOP
Page 291 and 292:
and treatment, has rarely been syst
Page 293 and 294:
uncontrolled massive bleeding affec
Page 295 and 296:
Results. A total of 396 patients we
Page 297 and 298:
C30 questionnaire, and the correspo
Page 299 and 300:
wave length of light of reflected r
Page 301 and 302:
0783 PREVALENCE OF MEMBRANE PROTEIN
Page 303 and 304:
erozygous mother has a more severe
Page 305 and 306:
0794 CARDIAC MANIFESTATIONS IN A BR
Page 307 and 308:
0799 INEFFECTIVE ERYTHROPOIESIS IN
Page 309 and 310:
p=0.014 and p=0.003, respectively).
Page 311 and 312:
0809 CURRENT APPROACH TO CHELATION
Page 313 and 314:
Thrombosis II 0814 UNSUSPECTED PULM
Page 315 and 316:
the 97.5th percentile (5.2 U/mL) ge
Page 317 and 318:
symptoms of DVT, 3 (7.89%) previous
Page 319 and 320:
Transfusion medicine and vascular b
Page 321 and 322:
tions (most bacterial, 2 malaria, 6
Page 323 and 324:
0844 INCREASED LEUKOCYTE-PLATELET I
Page 325 and 326:
0851 CORD BLOOD DERIVED MESENCHYMAL
Page 327 and 328:
SIMULTANEOUS SESSION II Chronic mye
Page 329 and 330:
0862 COMPARISON OF DASATINIB TO HIG
Page 331 and 332:
0867 COMPREHENSIVE GERIATRIC ASSESS
Page 333 and 334:
0872 MN1 INDUCES LEUKEMIA IN MICE A
Page 335 and 336:
0877 PAX5/TEL TRANSDUCED PRE-BI CEL
Page 337 and 338:
0882 CISPLATIN INDUCES THROMBIN GEN
Page 339 and 340:
have an early manifestation of typi
Page 341 and 342:
0892 INTEGRATION OF GENOME WIDE SNP
Page 343 and 344:
0897 THE PHENOTYPE OF JAK2V617F MUT
Page 345 and 346:
gest diverse sequences of NPM mutan
Page 347 and 348:
2004 to January, 2006. At enrollmen
Page 349 and 350:
with a p value of ≥ 0.10. Sets of
Page 351 and 352:
BRIC 126 and 4N1K) in cells lacking
Page 353 and 354:
sclerosis[NS] and 12 Mixed cellular
Page 355 and 356:
0927 MK-0457, A NOVEL MULTIKINASE I
Page 357 and 358:
Publication Only 0933 CLINICAL FEAT
Page 359 and 360:
HSCT from the available Asian as we
Page 361 and 362:
that the incidence of JAK2 mutation
Page 363 and 364:
without type 2 diabetes. Methods. T
Page 365 and 366:
pts (38.8%) that were isolated (abs
Page 367 and 368:
y using the Miltenyi CD34 isolation
Page 369 and 370:
0969 COMPARISON OF CD25 IMMUNOHISTO
Page 371 and 372:
cytes was 24 days (range 8-32 days)
Page 373 and 374:
a cytogenetic hallmark for M4/M5 su
Page 375 and 376:
normal human BM B progenitor cells
Page 377 and 378:
0994 INCIDENCE OF INVASIVE ASPERGIL
Page 379 and 380:
3 of disease relapse.TRM at day+100
Page 381 and 382:
survival of five years. This dismal
Page 383 and 384:
1011 FLOW CYTOMETRIC DNA INDEX AND
Page 385 and 386:
1018 THE EFFECT OF THE SUGARBAKER P
Page 387 and 388:
1024 KIR/HLA CLASS I MISMATCHING AN
Page 389 and 390:
ment details and thrombotic histori
Page 391 and 392:
1036 INCIDENCE AND SPECTRUM OF INFE
Page 393 and 394:
tinely by our stem cell lab prior t
Page 395 and 396:
tion to a translocation t(5;14)(q35
Page 397 and 398:
ment of CML and induces a high rate
Page 399 and 400:
due to reactivation and/or progress
Page 401 and 402:
1063 ABNORMAL METHYLATION STATUS OF
Page 403 and 404:
1069 CLINICAL RELEVANCE OF REGULATO
Page 405 and 406:
1076 SERUM LEVELS OF SOLUBLE HLA CL
Page 407 and 408:
patient is still undergoing intensi
Page 409 and 410:
nificant MVD differences were detec
Page 411 and 412:
dictor of OS (p=0.004). High dose t
Page 413 and 414:
1099 ALTERATIONS IN THE NATURAL KIL
Page 415 and 416:
1105 CYTOGENETIC ABNORMALITIES IN 3
Page 417 and 418:
1110 CONSTITUTIVE ACTIVATION OF STA
Page 419 and 420:
efficacy results with a well-tolera
Page 421 and 422:
unmutated VH genes, and high and lo
Page 423 and 424:
Aims. Aim of this study was to pred
Page 425 and 426:
tested across a wide range of human
Page 427 and 428:
were incidentally diagnosed (52%).
Page 429 and 430:
ß2GP1 may be considered as determi
Page 431 and 432:
characterized in 198 β thalassaemi
Page 433 and 434:
1155 PLATELET AGGREGATION IN CHILDR
Page 435 and 436:
to-pelvic or perineal trauma. No me
Page 437 and 438:
in age. High prevalence of LBM amon
Page 439 and 440:
ecause some of the patients were or
Page 441 and 442:
of the drug is crucial to allow lon
Page 443 and 444:
egarding cost analysis of ASCT in G
Page 445 and 446:
ID Allo-BMT, 1 family one mismatche
Page 447 and 448:
admitted to ICU were discharged des
Page 449 and 450:
events -Postoperative states: 9,19%
Page 451 and 452:
efficacy and decreased atherosclero
Page 453 and 454:
1217 INCIDENCE OF EARLY STAGE IDIOP
Page 455 and 456:
1691GA and 1 homozygous 1691AA. The
Page 457 and 458:
1230 ASSOCIATION OF HEPARANASE GENE
Page 459 and 460:
posed, was: DF = (CD43%+FMC7%+CD79b
Page 461 and 462:
treatment of acute promyelocityc le
Page 463 and 464:
loaded group and 35 (70%) were non-
Page 465 and 466:
mild. Fas and soluble Fas ligand le
Page 467 and 468:
1265 POSACONAZOLE THERAPY IN REFRAC
Page 469 and 470:
ly express the cytoplasmic (inactiv
Page 471 and 472:
findings confirmed the significant
Page 473 and 474:
a less favorable prognosis. Interes
Page 475 and 476:
disease (HD), 4 patients (9%) with
Page 477 and 478:
1295 HEMOPHAGOCYTIC LYMPHOHYSTIOCYT
Page 479 and 480:
phamide 750 mg/m 2 on day 1, vincri
Page 481 and 482:
nomenon is unclear. It has been sug
Page 483 and 484:
oped mild thrombocytopenia (platele
Page 485 and 486:
gle dose of 54mg/m 2 rituximab furt
Page 487 and 488:
patients (pts), 36 male, with acute
Page 489 and 490:
esulting alterations of the endothe
Page 491 and 492:
(range 1-7) and 28,6% of patients h
Page 493 and 494:
three decades. In vivo, Ara-C is tr
Page 495 and 496:
statistical analysis. Results. Seve
Page 497 and 498:
Results. Though there was no recogn
Page 499 and 500:
2% and 19% of patients with or with
Page 501 and 502:
were older than 65 y) which can be
Page 503 and 504:
1376 RESVERATROL INDUCED P53 MEDIAT
Page 505 and 506:
median time of 21 days to reach >0.
Page 507 and 508:
ly. Conclusions. 1. Combined intens
Page 509 and 510:
to the presence of IVS1-6 mutation
Page 511 and 512:
fy predictive factors for these abn
Page 513 and 514:
acute leukemia. However, we cannot
Page 515 and 516:
agents. They involve primarily the
Page 517 and 518:
voriconazole for 2 months followed
Page 519 and 520:
typed using a commercially availabl
Page 521 and 522:
low up of ABL KD mutations’ level
Page 523 and 524:
with development of BC/AP. 2. EVI-1
Page 525 and 526:
1447 THE IMPACT OF DISPARITY IN SHO
Page 527 and 528:
three had visual field defects, two
Page 529 and 530:
acquired mutation most prone to cau
Page 531 and 532:
1466 ROS GENERATION AND APOPTOSIS I
Page 533 and 534:
1473 DIARRHEIC SYNDROME, A CLINICAL
Page 535 and 536:
gene fusion is an independent progn
Page 537 and 538:
1484 EPIDEMIOLOGY AND RESPONSE TO T
Page 539 and 540:
1492 FREQUENCY OF MEDITERRANEAN GLU
Page 541 and 542:
immune globulin was administered at
Page 543 and 544:
maintained on Imatinib 400 mg. Afte
Page 545 and 546:
Hodgkin’s disease is well known,
Page 547 and 548:
gram provided a unique chance to de
Page 549 and 550:
even when ADP-induced plt activatio
Page 551 and 552:
medullary involvement of multiple m
Page 553 and 554:
1540 ADMINISTRATION OF G-CSF AND CH
Page 555 and 556:
1548 QUALITY ANALYSIS OF THE MULTID
Page 557 and 558:
Index of authors A Aapro, M., 0377,
Page 559 and 560:
Bahr, J., 0148 Bai, M., 1551 Baia,
Page 561 and 562:
Bottini, P.V., 1181 Botto, B., 0408
Page 563 and 564:
Chaidos, A., 0456, 0498, 0599, 0686
Page 565 and 566:
De Keersmaecker, K., 0442, 0875 De
Page 567 and 568:
El-Sharkawy, N., 0016 Elwahidi, G.,
Page 569 and 570:
Garcia-Frade, J., 0346, 0680, 1105
Page 571 and 572:
H Haas, N., 0742 Haas, O.A., 0001,
Page 573 and 574:
Jaksic, B., 0127, 0446 Jaksic, O.,
Page 575 and 576:
Körmöczi, G., 0848 Kornblau, S.,
Page 577 and 578:
Lin, L.-I., 0030, 0484 Lin, T., 012
Page 579 and 580:
Massé, A., 0249 Massó, P., 1287,
Page 581 and 582:
Musto, P., 0254, 0401, 0422, 0569,
Page 583 and 584:
Papadavid, E., 1442 Papageorgiou, E
Page 585 and 586:
Probatova, N., 0704 Prochazka, V.,
Page 587 and 588:
Rykavicin, O., 0504 Ryningen, A., 0
Page 589 and 590:
Sirard, C., 0127, 0128 Sirigou, A.,
Page 591 and 592:
Thiebaut, A., 0454 Thieblemont, C.,
Page 593 and 594:
Vincenzi, C., 1060 Viniou, N.-A., 0
Page 595 and 596:
Zouabi, H., 0503, 0999 Zoumbos, N.C
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603:
show all

12th Congress of the European Hematology ... - Haematologica

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?